What are your top takeaways from ASCO GI 2026?  

GLP1 agonist use is associated with improved outcomes for colorectal cancer in a retrospective United States study. Now we need to incorporate this into randomized trials. I think this also provides more evidence that metabolic syndrome type issues may help explain early-onset colorectal cancers. ...

I actually haven't looked into the other disease sites, but the clear practice-changing study is the HERIZON-GEA-01 study of zanidatamab + chemo for 1L HER2 + ve EGC. These data support that zanidatamab + chemo (+/- tislelizumab) is the new SoC, replacing the prior standard of pembrolizumab/tras...

In no particular order:HERIZON-GEA-01 continues the era of biomarker-driven care in gastroesophageal cancer (and again proves that HER2 targeting and immunotherapy are a false binary); the best comparator arm for zanidatamab + tislelizumab + chemo, though, would be against the KEYNOTE-811 quadruplet...

Abstract 13: BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).This is the expected updated follow-up to the BREAKWATER data presented last year. 147 patients were randomized (EC+FOLFIRI, n=73; control (FOL...

Here are my top 3 presentations from the ASCO GI:ILUSTRO study: This is a phase II multicohort study. At the ASCO GI 2026, the cohort 4 results were reported. This cohort evaluated zolbetuximab (a CLDN18.2-targeting monoclonal antibody) in addition to mFOLFOX6/nivolumab as first-line therapy for HER...

Targeted therapeutic approaches have again risen to the top of national/international conferences, and ASCO GI is no exception, resulting in significant benefits for patients. Importantly, these targeted approaches are increasingly investigated as initial therapy for patients with advanced disease, ...